Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://journals.lww.com/immunotherapy-journal/abstract/2010/10000/phase_2_trial_of_single_agent_ipilimumab.9.aspx, but it redirected us to https://journals.lww.com/immunotherapy-journal/abstract/2010/10000/phase_2_trial_of_single_agent_ipilimumab.9.aspx. The analysis below is for the second page.

Title[redir]:
Journal of Immunotherapy
Description:
pancreas adenocarcinoma with measurable disease, good performance status, and minimal comorbidities. Ipilimumab was administered intravenously (3.0 mg/kg every 3 wk; 4 doses/course) for a maximum of 2 courses. Response rate by response evaluation criteria in solid tumors criteria and toxicity were measured. Twenty-seven subjects were enrolled (metastatic disease: 20 and locally advanced: 7) with median age of 55 years (27 to 68 y) and good performance status (26 with Eastern Cooperative Oncology Group performance status =0 to 1). Three subjects experienced ≥ grade 3 immune-mediated adverse events (colitis:1, encephalitis:1, hypohysitis:1). There were no responders by response evaluation criteria in solid tumors criteria but a subject experienced a delayed response after initial progressive disease. In this subject, new metastases after 2 doses of Ipilimumab established progressive disease. But continued administration of the agent per protocol resulted in significant delayed regression of the primary lesion and 20 hepatic metastases. This was reflected in tumor markers normalization, and clinically significant improvement of performance status. Single agent Ipilimumab at 3.0 mg/kg/dose is ineffective for the treatment of advanced pancreas cancer. However, a significant delayed response in one subject of this trial suggests that immunotherapeutic approaches to pancreas cancer deserve further exploration....

Matching Content Categories {📚}

  • Health & Fitness
  • Education
  • Non-Profit & Charity

Content Management System {📝}

What CMS is doi.org built with?


Doi.org is powered by MYBB.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 76,079,999 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

The income method remains a mystery to us.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Doi.org has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

journal, advanced, ipilimumab, response, issue, disease, performance, status, criteria, access, subscribe, alerts, authors, abstract, phase, trial, agent, locally, metastatic, pancreatic, adenocarcinoma, cancer, subjects, pancreas, subject, delayed, significant, log, register, logo, articles, issues, rosenberg, single, richard, buy, tumor, regression, good, evaluation, solid, tumors, experienced, progressive, metastases, text, subscribers, request, article, browse,

Topics {✒️}

0b013e3181eec14c buy abstract advanced pancreatic cancer good performance status advanced pancreas cancer full text access pancreatic ductal adenocarcinoma journal authors submit metastatic pancreas adenocarcinoma initial progressive disease immunologic tumor regression solid tumors criteria tumor markers normalization clinically significant improvement pancreas cancer deserve artificial intelligence training significant delayed regression response evaluation criteria etoc alerts significant delayed response 0 mg/kg/dose single agent ipilimumab service request 800-638-3030 register subscribe performance status individual subscribers log journal tables locally advanced issue subject experienced metastatic disease trial suggests delayed response 0 mg/kg website subscribe measurable disease journal response rate center submit anti-ctla-4 effective therapies minimal comorbidities administered intravenously median age continued administration protocol resulted primary lesion immunotherapeutic approaches ido-1 inhibitor email inbox rights reserved

Questions {❓}

  • Not a Subscriber?

Social Networks {👍}(1)

External Links {🔗}(59)

Analytics and Tracking {📊}

  • Comscore
  • Google Analytics
  • Google Tag Manager

Libraries {📚}

  • Bootstrap
  • FontAwesome
  • jQuery
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Cookielaw
  • Jsdelivr
  • Scite
  • Wolterskluwer

5.09s.